CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hanx Biopharmaceuticals (Wuhan) Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hanx Biopharmaceuticals (Wuhan) Co Ltd
WUHAN, HUB  China Ticker: 33783378
Business Summary
Hanx Biopharmaceuticals Wuhan Co Ltd is a China-based company mainly engaged in the discovery, development and commercialization of products for precision therapies in cancers and autoimmune diseases. The Company’s core products include HX009, HX301, HX044, and HX008. HX009 is a bifunctional anti-PD-1 antibody SIRP fusion protein, aiming at enhancing PD-1 function and creating a PD-1 molecule. HX301 is a multi-targeted kinase inhibitor with a unique kinase inhibition profile. HX044 is a clinical-stage drug for treatment of various types of malignancies, particularly PD-1-resistant solid tumors. HX008 is a humanized antagonist mAb against human PD-1 by using human IgG4 isotype, which can inhibit the PD-1 signal to restore the capability of the immune cells to kill cancer cells through blocking PD-1 binding to their ligands PD-L1 and PD-L2.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman FamingZhang 60 8/22/2024 3/1/2024
Chief Executive Officer, Chief Scientific Officer, General Manager, Executive Director QixiangLi 64 8/22/2024 1/1/2022
Chief Financial Officer, Joint Company Secretary of Our Company The Secretary Of Our Board and Vice ZhangHui 56 8/1/2024 8/1/2024
9 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 136,218,830 (As of 12/23/2025)
Stock Exchange: HKG


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026